Genmab (GMAB)

Executive Summary

Genmab is a Denmark-based biotechnology company dedicated to the discovery and development of differentiated antibody therapeutics, with a primary focus on oncology. The company’s pipeline includes over 50 candidates, leveraging proprietary platforms such as DuoBody® for bispecific antibodies and HexaBody® for enhanced effector function. Genmab’s key commercial products are DARZALEX® (daratumumab), partnered with Johnson & Johnson for multiple myeloma, and KESIMPTA® (ofatumumab), partnered with Novartis for multiple sclerosis. These collaborations provide a strong royalty revenue stream that funds the company’s innovative pipeline. With a market capitalization of approximately $16.6 billion, Genmab is positioned as a leading mid-cap biotech with a track record of successful partnerships and a robust early-stage pipeline. Looking ahead, Genmab’s strategic focus is on advancing its wholly-owned pipeline and expanding the label of existing products. Key near-term catalysts include potential label expansions for epcoritamab (a CD3xCD20 bispecific antibody) in additional lymphoma subtypes, such as follicular lymphoma, where Phase 2 data may support regulatory filings. Additionally, updates on early-stage DuoBody and HexaBody candidates could provide proof-of-concept momentum. The company’s conviction score of 75 reflects its strong commercial base and promising pipeline, tempered by the inherent risks of clinical development and competition.

Upcoming Catalysts (preview)

• H2 2026Epcoritamab regulatory filing for relapsed/refractory follicular lymphoma70% success
• 2026Phase 2 data readout for GEN1057 (DuoBody) in advanced solid tumors50% success
• 2026DARZALEX label expansion (e.g., frontline multiple myeloma combination) update from partner J&J80% success